A novel TAp73-inhibitory compound counteracts stemness features of glioblastoma stem cells.

Mol Oncol · 2025 · PMC11887682 · PMID 39090849

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This decrease in the stemness marker was accompanied by a highly significant increase in the percentage of Tuj1+ and GFAP+ cells after 72 h of treatment under proliferating culture conditions (Fig. 6C ), all supporting the idea that this compound reduces the stemness potential of G144 cells.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.